Stock listing
Frankfurt:5J90 Fluicell AB Aktie
German listing (Frankfurt) of Fluicell AB · home listing Stockholm:FLUI
Follow Fluicell AB into a list and get an email when it puts out news.
Share price · FWB:5J90
€1.83 EUR -0.18 (-9.0%)
Close on Nov 20, 2026
Past year +136.9% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits- Day range
- €1.83 – €1.89 EURNov 20, 2026
- Market cap
- €2.51M EURAt the close on Nov 20, 2026 · price × 1.37M shares outstanding
- 52-week range
- €0.722 – €5.27 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €79 EURMedian day 0 shares · 55 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|
| Stockholm:FLUI · Home | 21.10 SEK | -1.90 (-8.3%) | 979 | 20.80 | 22.80 | 20.80 | 23.00 | Close on Nov 20, 2026 |
|---|
| Frankfurt:5J90 | €1.83 EUR | -0.18 (-9.0%) | — | €1.89 | €1.89 | €1.83 | €2.01 | Close on Nov 20, 2026 |
|---|
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:5J90 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|
| €2.492 | +0.149 | +6.4% | €2.332 | €2.503 | €2.316 | 0 |
|---|
| €2.343 | -0.068 | -2.8% | €2.373 | €2.374 | €2.333 | 0 |
|---|
| €2.411 | +0.083 | +3.6% | €2.417 | €2.418 | €2.38 | 0 |
|---|
| €2.328 | -0.033 | -1.4% | €2.328 | €2.328 | €2.328 | 0 |
|---|
| €2.361 | -0.107 | -4.3% | €2.50 | €2.511 | €2.355 | 0 |
|---|
| €2.468 | +0.025 | +1.0% | €2.451 | €2.495 | €2.448 | 0 |
|---|
| €2.443 | +0.044 | +1.8% | €2.443 | €2.443 | €2.443 | 0 |
|---|
| €2.399 | -0.013 | -0.5% | €2.399 | €2.399 | €2.399 | 0 |
|---|
| €2.412 | +0.018 | +0.8% | €2.412 | €2.412 | €2.412 | 0 |
|---|
| €2.394 | +0.063 | +2.7% | €2.40 | €2.40 | €2.394 | 0 |
|---|
| €2.331 | -0.057 | -2.4% | €2.331 | €2.331 | €2.331 | 0 |
|---|
| €2.388 | -0.086 | -3.5% | €2.388 | €2.388 | €2.388 | 0 |
|---|
| €2.474 | +0.019 | +0.8% | €2.474 | €2.474 | €2.474 | 0 |
|---|
| €2.455 | -0.053 | -2.1% | €2.468 | €2.468 | €2.448 | 0 |
|---|
| €2.508 | +0.09 | +3.7% | €2.508 | €2.508 | €2.508 | 0 |
|---|
| €2.418 | +0.114 | +4.9% | €2.418 | €2.418 | €2.418 | 0 |
|---|
| €2.304 | -0.173 | -7.0% | €2.304 | €2.304 | €2.304 | 0 |
|---|
| €2.477 | +0.158 | +6.8% | €2.477 | €2.477 | €2.477 | 0 |
|---|
| €2.319 | -0.179 | -7.2% | €2.397 | €2.405 | €2.312 | 0 |
|---|
| €2.498 | -0.023 | -0.9% | €2.498 | €2.498 | €2.498 | 0 |
|---|
| €2.521 | -0.005 | -0.2% | €2.535 | €2.552 | €2.493 | 0 |
|---|
| €2.526 | -0.037 | -1.4% | €2.526 | €2.526 | €2.526 | 0 |
|---|
| €2.563 | +0.029 | +1.1% | €2.586 | €2.596 | €2.558 | 0 |
|---|
| €2.534 | -0.083 | -3.2% | €2.534 | €2.534 | €2.534 | 0 |
|---|
| €2.617 | +0.03 | +1.2% | €2.617 | €2.617 | €2.617 | 0 |
|---|
| €2.587 | +0.042 | +1.7% | €2.551 | €2.587 | €2.55 | 1,000 |
|---|
| €2.545 | -0.046 | -1.8% | €2.555 | €2.56 | €2.519 | 0 |
|---|
| €2.591 | +0.012 | +0.5% | €2.591 | €2.591 | €2.591 | 0 |
|---|
| €2.579 | -0.018 | -0.7% | €2.579 | €2.579 | €2.579 | 0 |
|---|
| €2.597 | +0.028 | +1.1% | €2.577 | €2.605 | €2.555 | 0 |
|---|
| €2.569 | -0.04 | -1.5% | €2.615 | €2.616 | €2.564 | 0 |
|---|
| €2.609 | +0.038 | +1.5% | €2.609 | €2.609 | €2.609 | 0 |
|---|
| €2.571 | -0.079 | -3.0% | €2.624 | €2.624 | €2.557 | 0 |
|---|
| €2.65 | -0.069 | -2.5% | €2.665 | €2.672 | €2.641 | 0 |
|---|
| €2.719 | -0.012 | -0.4% | €2.719 | €2.719 | €2.719 | 0 |
|---|
| €2.731 | -0.105 | -3.7% | €2.731 | €2.731 | €2.731 | 0 |
|---|
| €2.836 | -0.012 | -0.4% | €2.836 | €2.836 | €2.836 | 0 |
|---|
| €2.848 | -0.05 | -1.7% | €2.848 | €2.848 | €2.848 | 0 |
|---|
| €2.898 | -0.025 | -0.9% | €2.898 | €2.898 | €2.898 | 0 |
|---|
| €2.923 | +0.105 | +3.7% | €2.923 | €2.923 | €2.923 | 0 |
|---|
| €2.818 | +0.209 | +8.0% | €2.818 | €2.818 | €2.818 | 0 |
|---|
| €2.609 | -0.012 | -0.5% | €2.609 | €2.609 | €2.609 | 0 |
|---|
| €2.621 | -0.061 | -2.3% | €2.63 | €2.653 | €2.608 | 0 |
|---|
| €2.682 | -0.061 | -2.2% | €2.682 | €2.682 | €2.682 | 0 |
|---|
| €2.743 | -0.022 | -0.8% | €2.743 | €2.743 | €2.743 | 0 |
|---|
| €2.765 | +0.081 | +3.0% | €2.765 | €2.765 | €2.765 | 0 |
|---|
| €2.684 | -0.009 | -0.3% | €2.684 | €2.684 | €2.684 | 0 |
|---|
| €2.693 | +0.043 | +1.6% | €2.693 | €2.693 | €2.693 | 0 |
|---|
| €2.65 | -0.171 | -6.1% | €2.65 | €2.65 | €2.65 | 0 |
|---|
| €2.821 | -0.358 | -11.3% | €2.821 | €2.821 | €2.821 | 0 |
|---|
| €3.179 | +0.078 | +2.5% | €3.179 | €3.179 | €3.179 | 0 |
|---|
| €3.101 | +0.026 | +0.8% | €3.101 | €3.101 | €3.101 | 0 |
|---|
| €3.075 | +0.225 | +7.9% | €3.075 | €3.075 | €3.075 | 0 |
|---|
| €2.85 | -0.078 | -2.7% | €2.85 | €2.85 | €2.85 | 0 |
|---|
| €2.928 | +0.165 | +6.0% | €2.928 | €2.928 | €2.928 | 0 |
|---|
| €2.763 | -0.048 | -1.7% | €2.763 | €2.763 | €2.763 | 0 |
|---|
| €2.811 | +0.301 | +12.0% | €2.701 | €2.82 | €2.666 | 680 |
|---|
Splits
1 split · FWB:5J90 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|
| 1-for-350 | Consolidation |
|---|
- Ticker
- Frankfurt:5J90
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
Fluicell AB on 6ix
- News releases
- 3 in all · newest Sep 2, 2025 · oldest 2020
- Decks
- 1 deck · latest May 22, 2023
Where Fluicell AB is listed
Valuation
EV/sales 1.6× against a median of 26.9×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 30.96M SEK
- P/E
- 10.4×
- EV/sales
- 1.6×
- EV/EBITDA
- 10.7×
- Price/book
- 1.8×
- Gross margin
- 91.6%
- Operating margin
- 12.9%
- Net margin
- 14.1%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|
| Fluicell AB · OMXSTO:FLUI | US$2.83M | US$3.03M | 10.4× | 1.6× | 10.7× | 1.8× | 14.1% | 0.1× | n/a |
|---|
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
|---|
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
|---|
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
|---|
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
|---|
| Gelteq Limited · NASDAQ:GELS | US$2.89M | US$6.27M | n/a | 57.2× | n/a | 0.3× | n/a | 0.4× | 0.83 |
|---|
| Curis, Inc. · NASDAQ:CRIS | US$2.85M | −US$1.42M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | 1.85 |
|---|
| Alligator Bioscience AB · OMXSTO:ATORX | US$2.79M | US$1.47M | n/a | 53.3× | n/a | 1.2× | n/a | 1.2× | n/a |
|---|
| Traws Pharma, Inc. · NASDAQ:TRAW | US$2.69M | US$351,448 | n/a | n/a | n/a | n/a | n/a | n/a | 2.07 |
|---|
| NextCell Pharma AB · OMXSTO:NXTCL | US$2.69M | US$626,140 | n/a | 0.6× | n/a | 0.6× | −440.8% | 0.0× | n/a |
|---|
| Bioxytran, Inc. · OTC:BIXT | US$2.66M | US$2.59M | n/a | n/a | n/a | n/a | n/a | n/a | -1.20 |
|---|
| Median of the others | US$2.87M | US$626,140 | | 26.9× | | 1.1× | −440.8% | 0.3× | 1.19 |
|---|
Team and board
Officers
| Officer | Role |
|---|
| Carolina Trkulja | CEO |
|---|
| Joakim Wahlberg | Chief Financial Officer |
|---|
| Gavin D. M. Jeffries | CHIEF TECHNOLOGY OFFICER |
|---|
| Jonas Hannestad | CHIEF MARKETING & COMMUNICATIONS OFFICER |
|---|
| Vladimir Kirejev | Senior R&D Scientist and Laboratory Manager |
|---|
Board
| Director | Role |
|---|
| Niklas Frisk | Chairman of the board |
|---|
| Abdul Kader | Board member |
|---|
| Alex Scheepers | Board member |
|---|
| Carl Fhager | Board member |
|---|
| Daniel T. Chiu | Board member |
|---|
| Karin Jennbacken | Board member |
|---|
| Owe Orwar | Board member |
|---|
| Peter Kjäll | Board member |
|---|
Events
| Quarter | Results | Share move |
|---|
| Q1 2024 | May 16, 2024 · After close | +1.8% |
|---|
| Q4 2023 | Jan 4, 2024 · After close | +3.3% |
|---|
Open Events
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Revenue | 6.00M | 1.86M | 3.34M | 3.25M | 2.60M | 4.63M | 2.49M | 1.23M | 1.05M | 2.63M |
|---|
| Cost of revenue | 14.7M | 1.59M | 1.60M | 663.0K | 715.0K | 988.0K | 443.0K | 391.0K | 8.49M | 7.59M |
|---|
| Gross profit | -8.69M | 3.76M | 1.74M | 2.59M | 1.89M | 3.65M | 2.04M | 835.0K | -7.44M | -4.96M |
|---|
| Selling, general and administrative | 11.9M | 14.4M | 18.6M | 16.9M | 9.94M | 7.13M | 8.32M | 7.43M | 3.96M | 4.65M |
|---|
| Operating income | -8.69M | -15.8M | -26.9M | -21.7M | -21.7M | -17.0M | -18.7M | -14.8M | -7.44M | -4.97M |
|---|
| Depreciation and amortization | 370.0K | 440.0K | 610.0K | 720.0K | 588.0K | 605.0K | 522.0K | 326.0K | 71.0K | 85.0K |
|---|
| EBITDA | -8.31M | -15.4M | -26.3M | -21.0M | -21.1M | -16.4M | -18.2M | -14.5M | -7.37M | -4.88M |
|---|
| Interest expense | 193.0K | 79.0K | 30.0K | 47.0K | 27.0K | 564.0K | 421.0K | 2.00K | 34.0K | 27.0K |
|---|
| Income before tax | -8.33M | -15.5M | -26.6M | -21.6M | -21.7M | -17.6M | -18.6M | -14.7M | -7.47M | -4.95M |
|---|
| Income tax | | | 442.1K | -120.0K | 27.0K | 564.0K | 398.1K | -78.0K | 34.0K | -16.0K |
|---|
| Net income | -8.33M | -15.5M | -26.6M | -21.5M | -21.7M | -18.2M | -18.6M | -14.7M | -7.47M | -4.95M |
|---|
| Earnings per share, basic | -6.07 | -13.10 | -25.45 | -0.32 | -0.37 | -0.33 | -62.24 | -52.95 | -35.86 | -37.72 |
|---|
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Cash and equivalents | 2.26M | 15.9M | 2.76M | 24.5M | 20.7M | 18.8M | 8.44M | 22.2M | 7.83M | 1.10M |
|---|
| Receivables | 2.20M | 1.38M | 1.24M | 2.79M | 1.93M | 1.77M | 1.67M | 529.0K | 1.44M | 820.0K |
|---|
| Inventory | 3.04M | 3.35M | 3.15M | 1.55M | 1.84M | 1.91M | 818.0K | 936.0K | 877.0K | 443.0K |
|---|
| Current assets | 7.60M | 20.7M | 7.61M | 29.2M | 24.8M | 22.9M | 11.3M | 24.0M | 10.8M | 2.50M |
|---|
| Property, plant and equipment | 445.0K | 1.14M | 1.54M | 2.30M | 1.84M | 1.60M | 1.83M | 1.49M | 206.0K | 273.0K |
|---|
| Total assets | 18.5M | 25.5M | 9.34M | 31.8M | 27.0M | 24.8M | 19.9M | 26.0M | 11.5M | 2.77M |
|---|
| Accounts payable | 1.30M | 897.0K | 1.50M | 858.0K | 1.05M | 736.0K | 1.87M | 854.0K | 759.0K | 226.0K |
|---|
| Current liabilities | 7.57M | 6.05M | 8.91M | 8.32M | 7.87M | 5.33M | 9.71M | 2.60M | 1.95M | 861.0K |
|---|
| Long-term debt | | | | | | | | | 0 | |
|---|
| Total debt | | | | | | | 5.00M | | 73.0K | 220.0K |
|---|
| Total liabilities | 7.57M | 6.27M | 8.91M | 8.32M | 7.87M | 5.33M | 9.71M | 2.60M | 1.95M | 934.0K |
|---|
| Shareholders' equity | 10.9M | 19.2M | 425.0K | 23.4M | 19.1M | 19.5M | 10.2M | 23.4M | 9.58M | 1.84M |
|---|
| Shares outstanding | 1.37M | 1.18M | 1.04M | 67.7M | 59.2M | 55.1M | 299.4K | 277.6K | 208.3K | 131.2K |
|---|
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Cash from operations | -4.95M | -15.7M | -27.2M | -21.0M | -18.6M | -17.6M | -17.1M | -12.5M | -7.83M | -5.50M |
|---|
| Capital spending | -4.95M | -3.49M | 0 | -1.14M | -772.0K | -331.0K | -812.0K | -1.56M | -500.0K | -83.0K |
|---|
| Free cash flow | -13.6M | -15.7M | -27.2M | -22.2M | -19.4M | -17.9M | -17.9M | -14.0M | -8.33M | -5.58M |
|---|
| Cash from investing | -8.67M | -3.49M | 0 | -1.14M | -772.0K | -331.0K | -812.0K | -1.56M | -500.0K | -83.0K |
|---|
| Cash from financing | 0 | 32.3M | 5.53M | 25.9M | 21.3M | 28.3M | 4.09M | 28.4M | 15.1M | 5.93M |
|---|
| Dividends paid | | | | | | | -5.00M | | | |
|---|
| Share buybacks | 0 | 39.5M | 3.87M | 31.7M | 23.2M | 30.8M | -6.40M | 33.7M | 16.4M | 6.10K |
|---|
| Change in cash | -13.7M | 13.2M | -21.7M | 3.76M | 1.89M | 10.4M | -13.8M | 14.4M | 6.73M | 353.0K |
|---|
Open Financials
Cap table
Built by 6ix from Fluicell AB’s releases
- Common shares
- 1,373,703
- Fully diluted
- 1,373,703
Fully diluted
| Line | Shares |
|---|
| Common shares | 1,373,703 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 1,373,703 |
|---|
Open Cap table
Shareholders
| Trade | Trade | Shares | Price | Value | Date |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 204 | SEK 11.00 | SEK 2,244 | Mar 13, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 600 | SEK 11.00 | SEK 6,600 | Mar 6, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 39 | SEK 10.91 | SEK 425 | Mar 5, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 1,000 | SEK 10.20 | SEK 10,200 | Jan 19, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 1,000 | SEK 10.50 | SEK 10,500 | Jan 13, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 7 | SEK 10.20 | SEK 71 | Jan 12, 2026 |
|---|
| Joakim Wahlberg Chief Financial Officer (CFO) | Buy | 1,000 | SEK 10.30 | SEK 10,300 | Dec 9, 2025 |
|---|
Open Shareholders
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Abdul Kader | Board member · Since at least Nov 5, 2026 |
|---|
| Alex Scheepers | Board member · Since at least Nov 4, 2026 |
|---|
| Carl Fhager | Board member · Since at least Nov 5, 2026 |
|---|
| Carolina Trkulja | CEO · Since at least Nov 5, 2026 |
|---|
| Daniel T. Chiu | Board member · Since at least Nov 5, 2026 |
|---|
| Gavin D. M. Jeffries | CHIEF TECHNOLOGY OFFICER · Since at least Nov 5, 2026 |
|---|
| Joakim Wahlberg | Chief Financial Officer · Since at least Nov 5, 2026 |
|---|
| Jonas Hannestad | CHIEF MARKETING & COMMUNICATIONS OFFICER · Since at least Nov 5, 2026 |
|---|
| Karin Jennbacken | Board member · Since at least Nov 5, 2026 |
|---|
| Niklas Frisk | Chairman of the board · Since at least Nov 5, 2026 |
|---|
All 13 people
| Person | Seat |
|---|
| Owe Orwar | Board member · Since at least Nov 5, 2026 |
|---|
| Peter Kjäll | Board member · Since at least Nov 5, 2026 |
|---|
| Vladimir Kirejev | Senior R&D Scientist and Laboratory Manager · Since at least Nov 5, 2026 |
|---|
Open People
Log in to ask 6ix AI your own questions about Fluicell AB.